Intellia Therapeutics Valuation
| NTLA Stock | USD 15.62 0.41 2.70% |
At this time, the firm appears to be overvalued. Intellia Therapeutics retains a regular Real Value of $14.13 per share. The prevalent price of the firm is $15.62. Our model calculates the value of Intellia Therapeutics from evaluating the firm fundamentals such as Return On Asset of -0.28, return on equity of -0.52, and Shares Outstanding of 101.85 M as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Intellia Therapeutics' valuation include:
Price Book 1.6527 | Enterprise Value 1 B | Enterprise Value Ebitda (5.51) | Price Sales 36.9234 | Enterprise Value Revenue 24.0074 |
Overvalued
Today
Please note that Intellia Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Intellia Therapeutics is based on 3 months time horizon. Increasing Intellia Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Intellia Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Intellia Stock. However, Intellia Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.62 | Real 14.13 | Target 83.25 | Hype 15.62 | Naive 16.97 |
The real value of Intellia Stock, also known as its intrinsic value, is the underlying worth of Intellia Therapeutics Company, which is reflected in its stock price. It is based on Intellia Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Intellia Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Intellia Therapeutics helps investors to forecast how Intellia stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Intellia Therapeutics more accurately as focusing exclusively on Intellia Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Intellia Therapeutics' intrinsic value based on its ongoing forecasts of Intellia Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Intellia Therapeutics' closest peers. If more than one evaluation category is relevant for Intellia Therapeutics we suggest using both methods to arrive at a better estimate.
Intellia Therapeutics Cash |
|
Intellia Valuation Trend
Comparing Intellia Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Intellia Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Intellia Therapeutics Total Value Analysis
Intellia Therapeutics is now expected to have valuation of 1.03 B with market capitalization of 1.59 B, debt of 115.35 M, and cash on hands of 874.28 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Intellia Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.03 B | 1.59 B | 115.35 M | 874.28 M |
Intellia Therapeutics Investor Information
About 91.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.65. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Intellia Therapeutics recorded a loss per share of 5.45. The entity had not issued any dividends in recent years. Based on the key indicators related to Intellia Therapeutics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Intellia Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Intellia Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Intellia Therapeutics has an asset utilization ratio of 2.79 percent. This suggests that the Company is making $0.0279 for each dollar of assets. An increasing asset utilization means that Intellia Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Intellia Therapeutics Ownership Allocation
Intellia Therapeutics has a total of 101.85 Million outstanding shares. The majority of Intellia Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Intellia Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Intellia Therapeutics. Please pay attention to any change in the institutional holdings of Intellia Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Intellia Therapeutics Profitability Analysis
The company reported the previous year's revenue of 36.27 M. Net Loss for the year was (481.19 M) with loss before overhead, payroll, taxes, and interest of (367.86 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Intellia Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Intellia Therapeutics and how it compares across the competition.
About Intellia Therapeutics Valuation
The stock valuation mechanism determines Intellia Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Intellia Therapeutics. We calculate exposure to Intellia Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Intellia Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 27.3 M | 18 M | |
| Pretax Profit Margin | (13.27) | (12.60) | |
| Operating Profit Margin | (14.21) | (13.49) | |
| Net Loss | (13.27) | (12.60) | |
| Gross Profit Margin | 0.75 | 0.79 |
Intellia Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 88.8 M |
Intellia Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Intellia Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Intellia we look at many different elements of the entity such as Intellia's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Intellia Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Intellia Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Intellia Therapeutics' worth.Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |